Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire Adderall XR Sales Suspended In Canada; FDA Stands By “Black Box”

Executive Summary

Differences between FDA and Health Canada's regulatory responses to adverse event reports for Adderall XR are likely to raise more questions about FDA's drug safety review process

You may also be interested in...



ADHD Class Warnings Could Be Strengthened Pending FDA Research

Despite FDA's recent approval of class warning language for attention deficit/hyperactivity disorder treatments, the agency will continue research in an effort to better characterize the extent of stimulant side effects in ADHD patients, Division of Psychiatry Products Director Thomas Laughren indicated

ADHD Class Warnings Could Be Strengthened Pending FDA Research

Despite FDA's recent approval of class warning language for attention deficit/hyperactivity disorder treatments, the agency will continue research in an effort to better characterize the extent of stimulant side effects in ADHD patients, Division of Psychiatry Products Director Thomas Laughren indicated

Shire Daytrana ADHD Patch To Launch In Early July With Some Class Labeling

Shire and manufacturing partner Noven expect an early July launch for Daytrana, the first transdermal patch for the treatment of attention deficit/hyperactivity disorder to receive FDA approval

Related Content

Topics

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel